CalciMedica, Inc. (CALC)

5.18 0.00 (0.00%) At close: 04:00PM EDT

CalciMedica, Inc.

505 Coast Boulevard South
Suite 307
La Jolla, CA 92037
United States
858-952-5500
https://www.calcimedica.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 13

Key executives

Name	Title	Pay	Exercised	Year born
Dr. A. Rachel Leheny Ph.D.	CEO & Director	852.84k	N/A	1963
Mr. Eric W. Roberts	Chief Business Officer & Vice Chairman of the Board	757.4k	N/A	1964
Dr. Kenneth A. Stauderman Ph.D.	Co-Founder & Chief Scientific Officer	615.59k	N/A	1953
Mr. Michael J. Dunn M.B.A., MBA	President & COO	N/A	N/A	1956
Dr. Anjana Rao Ph.D.	Co-Founder and Scientific Advisor	N/A	N/A	N/A
Dr. Patrick Hogan Ph.D.	Co-Founder and Scientific Advisor	N/A	N/A	N/A
Dr. Stefan Feske M.D.	Co-Founder and Scientific Advisor	N/A	N/A	N/A
Mr. Daniel E. Geffken M.B.A.	Interim Chief Financial Officer	N/A	N/A	1957
Cindy Reiedenberg	Accountant	N/A	N/A	N/A
Mr. John M. Dunn J.D.	General Counsel	N/A	N/A	1952

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. It also develops CM6336, an oral CRAC channel inhibitors for chronic inflammatory indications; and Auxora, for the treatment of acute ulcerative colitis and allergic asthma. The company is based in La Jolla, California.

Corporate governance

CalciMedica, Inc.’s ISS governance QualityScore as of 1 June 2024 is 9. The pillar scores are Audit: 10; Board: 8; Shareholder rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.